Mounjaro (tirzepatide) produced greater average weight loss than Ozempic (semaglutide) in the head-to-head SURPASS-2 trial, but with neuropathy or a foot ulcer the choice also depends on protecting muscle, balance and nutrition. Both are prescription weekly injections; rapid weight loss during active wound healing should be avoided and protein intake monitored.
Both medicines are prescription injections used to improve glucose management in adults with type 2 diabetes. They can also reduce body weight, although their approved indications and formulations differ.
For patients with diabetic foot complications, rapid weight loss without adequate nutrition may create additional challenges.
This guide compares Mounjaro vs Ozempic, explains the clinical evidence and outlines when treatment may need to wait.
Key Takeaways
-
Mounjaro contains tirzepatide, while Ozempic contains semaglutide.
-
Both are administered as weekly injections.
-
SURPASS-2 found greater average weight loss with tirzepatide than semaglutide 1 mg.
-
Weight loss can include reductions in both fat mass and lean mass.
-
Patients with neuropathy may already have weakness, balance problems or reduced mobility.
-
An active foot ulcer is not an automatic contraindication, but poor nutrition, dehydration or serious illness can complicate treatment.
-
Nausea, vomiting, diarrhoea and constipation are common side effects.
-
Treatment should be prescribed and monitored by a qualified diabetes physician or endocrinologist.
How Do Mounjaro and Ozempic Differ?
Mounjaro and Ozempic work through related but different hormonal pathways.
Both medicines help regulate blood glucose and reduce appetite.
What Is Mounjaro?
Mounjaro contains tirzepatide.
It activates two hormone receptors:
-
Glucose-dependent insulinotropic polypeptide (GIP)
-
Glucagon-like peptide-1 (GLP-1)
These pathways help regulate glucose-dependent insulin secretion, glucagon activity, appetite and gastric emptying.
Tirzepatide is usually started at a low weekly dose and increased gradually according to the prescribing information and patient tolerance.
What Is Ozempic?
Ozempic contains semaglutide.
It is a GLP-1 receptor agonist that improves glucose-dependent insulin secretion, reduces inappropriate glucagon secretion and slows gastric emptying.
It can also reduce appetite and support weight loss.
The starting dose is usually 0.25 mg once weekly, followed by gradual escalation according to the product label.
Mounjaro vs Ozempic: Comparison Table
| Feature | Mounjaro | Ozempic |
|---|---|---|
| Active molecule | Tirzepatide | Semaglutide |
| Mechanism | Dual GIP and GLP-1 receptor agonist | GLP-1 receptor agonist |
| Administration | Once-weekly injection | Once-weekly injection |
| Typical starting dose | 2.5 mg weekly | 0.25 mg weekly |
| Dose escalation | Gradual, according to response and tolerance | Gradual, according to response and tolerance |
| Weight loss in SURPASS-2 | Greater average reduction at studied doses | Lower average reduction at the 1 mg comparator dose |
| Common side effects | Nausea, diarrhoea, vomiting, constipation | Nausea, diarrhoea, vomiting, constipation |
| Important precautions | GI intolerance, dehydration, pancreatitis concerns, gallbladder events and other label warnings | Similar precautions |
| Muscle monitoring | Important during substantial weight loss | Important during substantial weight loss |
| Contraindications | Follow applicable product label, including MTC/MEN2 warnings where specified | Follow applicable product label, including MTC/MEN2 warnings where specified |
| Monitoring | Glucose, nutrition, hydration, adverse effects and weight | Glucose, nutrition, hydration, adverse effects and weight |
The exact available doses, indications and contraindications depend on the product's authorised prescribing information.
What Did the SURPASS-2 Trial Show?
The SURPASS-2 trial, published in The New England Journal of Medicine in 2021, compared tirzepatide with semaglutide in adults with type 2 diabetes inadequately controlled on metformin.
The trial included 1,879 participants.
Participants received:
-
Tirzepatide 5 mg weekly
-
Tirzepatide 10 mg weekly
-
Tirzepatide 15 mg weekly
-
Semaglutide 1 mg weekly
The treatment period was 40 weeks.
Average Weight Loss in SURPASS-2
| Treatment Group | Average Weight Change at 40 Weeks |
|---|---|
| Tirzepatide 5 mg | −7.6 kg |
| Tirzepatide 10 mg | −9.3 kg |
| Tirzepatide 15 mg | −11.2 kg |
| Semaglutide 1 mg | −5.7 kg |
Tirzepatide also produced greater average HbA1c reductions than semaglutide 1 mg in this trial.
What Do These Results Mean?
The results show that tirzepatide produced greater average weight loss at the studied doses.
However, several limitations matter.
SURPASS-2 did not specifically study patients with active diabetic foot ulcers.
It also did not compare tirzepatide with every available semaglutide dose.
Therefore, the findings cannot establish that Mounjaro is automatically the better choice for every patient with neuropathy or a foot ulcer.
Does Greater Weight Loss Mean Better Foot Healing?
Not necessarily.
Weight reduction may improve some metabolic risk factors, but diabetic foot ulcer healing depends on additional factors.
These include:
-
Blood supply
-
Pressure relief
-
Infection control
-
Wound care
-
Nutrition
-
Mobility
-
Overall medical condition
Greater weight loss does not automatically translate into faster ulcer healing.
Why Does Muscle Loss Matter for Diabetic Neuropathy?
Substantial weight loss can involve loss of both fat mass and lean mass.
Lean mass includes muscle and other non-fat tissues.
This is important for people with diabetic neuropathy because they may already have impaired balance, reduced sensation or muscle weakness.
How Can Muscle Loss Affect the Feet?
Muscles help support:
-
Standing balance
-
Walking stability
-
Joint movement
-
Posture
-
Safe transfers
-
Daily physical activity
A patient who loses muscle strength may become less stable while walking.
For someone with reduced foot sensation, poor balance can increase the risk of falls or accidental foot injuries.
Does Ozempic Cause Muscle Loss?
Weight loss during semaglutide treatment can include a reduction in lean mass.
However, this does not mean that every reduction in lean mass represents the same degree of muscle weakness.
Body-composition measurements and functional strength assessments provide different information.
The same consideration applies to tirzepatide.
How Can Patients Protect Muscle During Treatment?
Strategies may include:
-
Adequate protein intake
-
Avoiding excessively restrictive diets
-
Appropriate resistance exercise
-
Monitoring unintended weakness
-
Reviewing nutritional deficiencies
-
Assessing balance and mobility
Exercise must be adapted when a patient has an active foot ulcer.
For example, weight-bearing exercise may be inappropriate when strict offloading is prescribed.
A physiotherapist or treating clinician may recommend suitable non-weight-bearing activities.
How Much Protein Is Needed?
Protein requirements depend on body weight, kidney function, nutritional status and wound severity.
Patients with active ulcers may have increased nutritional needs, but a universal high-protein target is not appropriate for everyone.
A diabetes physician or dietitian should individualise intake, particularly when kidney disease is present.
Patients can explore diet and nutrition for broader nutritional guidance.
Can Mounjaro or Ozempic Affect Foot Ulcer Healing?
Weight loss and improved blood glucose control may support long-term metabolic health, but they do not automatically mean diabetes has gone away. Some people with type 2 diabetes may achieve remission after sustained weight loss, although ongoing monitoring remains important. Read more about Diabetes remission explained to understand what remission means, how doctors confirm it and why follow-up care remains necessary.
Their primary role in this context is metabolic management.
Improved glucose control may support the overall treatment plan, but medication-related appetite suppression and gastrointestinal symptoms can create nutritional challenges.
Why Does Nutrition Matter During Wound Healing?
Wound repair requires adequate energy, protein, vitamins and minerals.
If nausea or reduced appetite leads to insufficient food intake, nutritional status may deteriorate.
This can be particularly concerning in patients with large wounds, infection or recent surgery.
Can Dehydration Become a Problem?
Yes.
Vomiting and diarrhoea can cause dehydration.
This may worsen kidney function, particularly in vulnerable patients.
Patients with persistent gastrointestinal symptoms should contact their prescribing clinician.
Is an Active Foot Ulcer a Reason to Stop Treatment?
Not automatically.
An uncomplicated ulcer does not itself constitute a standard contraindication to tirzepatide or semaglutide.
However, severe infection, poor oral intake, dehydration or an upcoming procedure may justify reviewing whether to start, continue or temporarily interrupt treatment.
The decision should be individualised.
Why Is Offloading Still Essential?
Even with improved blood glucose, a plantar foot ulcer may fail to heal if pressure continues.
Offloading, wound management and circulation assessment remain central to treatment.
For more information about metabolic management, see the metabolic health and remission clinic.
What Drives the Monthly Cost of Mounjaro and Ozempic in India?
Patients frequently compare the Mounjaro price in India with the cost of semaglutide.
However, monthly treatment costs depend on more than the medicine's brand name.
Prices can change with dose, device presentation, availability and pharmacy pricing.
Main Cost Drivers
| Cost Factor | Why It Matters |
|---|---|
| Dose strength | Different strengths may have different prices |
| Device presentation | Single-dose and multi-dose devices may have different costs |
| Treatment duration | Ongoing therapy creates recurring expenses |
| Pharmacy pricing | Prices may vary between authorised sellers |
| Consultation fees | Prescribing and follow-up appointments add to total cost |
| Blood tests | Glucose, kidney function and other tests may be required |
| Nutrition support | Dietitian review may be useful |
| Side-effect management | Additional treatment may be necessary if adverse effects occur |
Why Should Patients Avoid Comparing Only One Injection Price?
A single pen or vial price may not represent the cost of a full month.
The number of doses supplied and the prescribed strength must be considered.
Patients should request a written estimate from an authorised pharmacy using the exact prescribed product and presentation.
Is the Cheaper Medicine Always Better?
No.
Treatment selection should consider:
-
Diabetes control
-
Clinical indication
-
Cardiovascular and kidney-related considerations
-
Side-effect tolerance
-
Nutritional status
-
Cost
-
Availability
-
Patient preferences
The prescribing physician should balance clinical suitability and affordability.
Who Should Wait Before Starting Either Injection?
Some patients may benefit from delaying initiation until their health is more stable.
This does not mean every patient with neuropathy or a foot ulcer must avoid treatment.
Wait-Before-Starting Checklist
- Active foot ulcer with significant illness or poor nutritional intake
-
Persistent vomiting or dehydration
-
Suspected severe gastroparesis
-
Rapid unintentional weight loss or marked weakness
-
Planned surgery requiring medication and anaesthesia review
-
Unresolved contraindications or important safety concerns
-
No reliable plan for diabetes monitoring and follow-up
What Is Gastroparesis?
Gastroparesis is delayed stomach emptying.
Symptoms can include:
-
Persistent nausea
-
Vomiting
-
Early fullness
-
Bloating
-
Difficulty tolerating meals
Because tirzepatide and semaglutide slow gastric emptying, they may be unsuitable for patients with severe gastroparesis.
Who Should Not Use These Medicines?
Patients must follow the contraindications in the applicable prescribing information.
Important considerations include:
Medullary thyroid carcinoma (MTC): A rare form of thyroid cancer. Some product labels contraindicate treatment in patients with a personal or family history of MTC.
Multiple endocrine neoplasia type 2 (MEN2): An inherited condition associated with certain endocrine tumours. It is also a labelled contraindication in some jurisdictions.
Other important concerns include serious hypersensitivity reactions, pancreatitis, severe gastrointestinal adverse effects and pregnancy-related restrictions.
A history of pancreatitis requires careful clinical consideration, although the exact prescribing restrictions depend on the product label.
Patients should not use either medicine during pregnancy unless the applicable prescribing information and specialist guidance specifically support its use; these medicines are generally avoided during pregnancy.
What Should Doctors Monitor During Treatment?
Monitoring should extend beyond body weight.
For patients with diabetic neuropathy or a foot ulcer, clinicians may assess several areas.
1. Blood Glucose
The diabetes physician reviews HbA1c, home glucose records or CGM data when appropriate.
2. Weight and Nutritional Intake
Rapid weight changes, reduced appetite and inadequate protein intake should be assessed.
3. Muscle Strength and Mobility
Functional assessments may include:
-
Grip strength
-
Walking ability
-
Balance
-
Difficulty rising from a chair
-
Falls or near-falls
These assessments should be adapted to foot offloading restrictions.
4. Foot Ulcer Progress
The foot-care team evaluates:
-
Wound size
-
Infection
-
Pressure relief
-
Circulation
-
Skin condition
-
Changes in mobility
5. Side Effects
Persistent vomiting, severe abdominal pain, dehydration or significant weakness require medical review.
6. Other Diabetes Medicines
When tirzepatide or semaglutide is used with insulin or a sulfonylurea, the risk of hypoglycaemia may increase.
The prescribing clinician may need to adjust treatment.
How Often Should Follow-Up Occur?
Follow-up frequency depends on dose escalation, glucose control, adverse effects and the severity of the foot condition.
Some patients require closer monitoring during initiation.
The treating clinicians should determine the appropriate schedule rather than relying on one fixed interval.
Mounjaro Doctor in Vizianagaram: Who Should Assess Treatment Suitability?
Patients searching for a mounjaro doctor in vizianagaram should consult a qualified diabetes physician or endocrinologist who can assess whether tirzepatide or semaglutide is appropriate for their medical condition.
At Elegance Diabetic Foot & Ulcer Clinic (EDFC), Dr. Ashutosh A Shah, MBBS, MS, MCh, DNB, a Plastic and Reconstructive Surgeon, is associated with complex diabetic foot assessment and treatment planning.
The diabetes physician should make prescribing and medication-adjustment decisions, while the foot-care team evaluates neuropathy, ulcer healing, pressure management and mobility.
Coordinated care is especially important when weight loss, reduced appetite or changes in physical activity affect recovery.
Patients who need specialist medication assessment can seek an endocrinologist opinion.
Conclusion
The Mounjaro vs Ozempic decision is more complicated when a patient has diabetic neuropathy or an active foot ulcer.
SURPASS-2 demonstrated greater average weight reduction with tirzepatide than semaglutide 1 mg, but weight loss alone does not determine the best treatment.
Muscle strength, balance, nutrition, hydration, wound status and medical safety must also be considered.
An active ulcer does not automatically prevent treatment, although severe illness, poor oral intake or other complications may justify delaying initiation.
The diabetes physician should prescribe and monitor the medicine, while the diabetic foot team manages the wound and related mobility concerns.
The goal is to improve metabolic health without compromising nutrition, physical function or foot recovery.
quiz Frequently Asked Questions
This article is general education, not a diagnosis. If you have a diabetic foot wound, please have it assessed in person. Send a photo on WhatsApp or book a consultation.
About the Author
Dr. Ashutosh Shah, Plastic, Reconstructive & Diabetic Foot Surgeon, Elegance Diabetic Foot & Ulcer Clinic, Surat
Dr. Ashutosh Shah is a board certified plastic and reconstructive surgeon with over 22 years of experience and more than 10,000 limbs and feet saved. He founded Elegance Diabetic Foot & Ulcer Clinic, India's first chain of clinics dedicated to foot care, with centres in Surat and OPD partners across South Gujarat. He is known for a limb first approach, safe wound care and ethical, natural results.


